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Unfortunately, the original publication of this article contains an error in table 1. The revised version of Table [1](#Tab1){ref-type="table"} is updated here. The original article has been corrected.Table 1Quality assessment of the included studies using the Methodological Index for Non-Randomized Studies (MINORS) criteriaAuthorsYearJournal/meetingEvidenceStudy design12345678TotalAchtnich et al. \[1\]2016ArthroscopyIIIProspective2212122012Ateschrang et al. \[2\]2017KSSTAIVCase series2222011010Büchler et al. \[11\]2016KneeIVCase series2212012010Häberli et al. \[25\]2018KneeIVCase series2212022011Heusdens et al. \[31\]2018KSSTAIVCase series2221012111Hoffmann et al. \[33\]2017J Orthop Surg ResIVCase series2202122011Hoogeslag et al. \[35\]2019Am J Sports MedIRCT2222122215Jonkergouw et al. \[38\]2018KSSTAIIIRetrospective2212012010Kohl et al. \[41\]2016BJJIVCase series1222022011Krismer et al. \[43\]2017KSSTAIV^a^Case series2202022010Meister et al. \[52\]2017KSSTAIVCase series2122012010Mukhopadhyay et al. \[54\]2018Chin J TraumatolIVCase series1222022011Osti et al. \[62\]2019KSSTAIVCase series2221012010Only the non-comparative part of the MINORS criteria was used (i.e. first 8 questions). The criteria of MINORS \[70\] with 0 points when not reported, 1 when reported but not adequate, and 2 when reported and adequate. Maximum score is 161. A clearly stated aim: the question addressed should be precise and relevant in the light of available literature2. Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion)3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study4. End points appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. In addition, the end points should be assessed on an intention-to-treat basis5. Unbiased assessment of the study end point: blind evaluation of objective end points and double-blind evaluation of subjective end points. Otherwise, the reasons for not blinding should be stated6. Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events7. Loss to follow-up less than 5%: all patients should be included in the follow-up. Otherwise, the proportion lost to follow-up should not exceed the proportion experiencing the major end point8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% CI, according to the expected incidence of the outcome event, and information about the level for statistical^a^This study reported being a level II study but we have classified this case series with failure analysis as level IV study
